Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial

Rolando Ochoa-Azze, Arturo Chang Monteagudo, Yanet Climent-Ruíz, Consuelo Macías Abraham, Carmen Valenzuela‐Silva, María de los Ángeles García-García, Yanet Jerez-Barceló, Yenisey Triana-Marrero, Laura Ruiz-Villegas, Luis Dairon Rodríguez-Prieto, Pedro Pablo Guerra-Chaviano, Belinda Sánchez-Ramírez, Tays Hernández-García, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, Fabrizio Chiodo, Andrea Calcagno, Valeria Ghisetti, Mireida Rodríguez-Acosta, Enrique Noa-Romero, Juliet Enríquez-Puertas, Darién Ortega-León, Irinia Valdivia-Álvarez, Aurora Delahanty-Fernández, Ariel Palenzuela-Díaz, Laura Rodríguez-Noda, Raúl González-Mugica, Yury Valdés-Balbín, Dagmar García-Rivera, Vicente Vérez-Bencomo